findmyKOL
Clinical trialNCT02642094TerminatedPhase 2Interventional

Aging Mammary Stem Cells and Breast Cancer Prevention

SponsorLuZhe SunEnrollment58Cancer of Breast
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

To examine whether rapamycin can reduce malignant markers and aberrant mammary stem/progenitor cells (MaSCs) number in surgical specimens

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

  • Ismail Jatoi, MD

    The University of Texas Health Science Center at San Antonio

    Principal Investigator
  • LuZhe Sun, PhD

    University of Texas Health Science Center San Antonio, Co-PI

    Principal Investigator

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • University of Texas Health Science Center San Antonio

    San Antonio, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 Jul 2016
Primary completion
1 Mar 2022
Completion
1 May 2022
Last update posted
5 Dec 2023
Registered enrollment
58
Registry id
NCT02642094

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.